Copyright © 2024 MarketWatch, Inc. All rights reserved.

In a report released today, Charles Pitman CFA from Barclays reiterated a Buy rating on UCB SA (0NZT – Research Report), with a price target of €240.00. The company’s shares closed last ...

Dr. Collins brings extensive drug development and clinical expertise in epilepsy --NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 ...

New Jersey-based pharmaceutical company UCB has sued to protect its patents for a Parkinson’s drug after an India-based ...

UCB and No­var­tis end­ed de­vel­op­ment on the lead pro­gram in their part­ner­ship af­ter re­port­ing a Phase 2a fail­ure in Parkin­son’s dis­ease.

After hours: January 2 at 6:20:44 PM EST ...

Please view our affiliate disclosure. Creating a strong brand identity is one of the most important aspects of a business. A well-designed logo is often the first impression a company makes on ...

Between 2018 and 2024, Saifuzzaman, despite his official position as a cabinet minister, is said to have orchestrated a takeover of UCB by placing his family members and associates in key ...

Roche already has one Alzheimer’s candidate in its pipeline targeting tau, but has added a second via a deal with Belgian drugmaker UCB worth up to $2 billion. The Swiss pharma group is paying $ ...